Loading...
XSHE002603
Market cap3.59bUSD
Jan 17, Last price  
15.75CNY
1D
0.38%
1Q
-6.25%
Jan 2017
27.94%
IPO
21.43%
Name

Shijiazhuang Yiling Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002603 chart
P/E
19.46
P/S
2.55
EPS
0.81
Div Yield, %
3.17%
Shrs. gr., 5y
-0.09%
Rev. gr., 5y
16.47%
Revenues
10.32b
-17.67%
938,555,9531,632,330,9861,649,320,0721,953,211,4301,648,676,3442,490,161,5332,921,157,2573,184,752,3683,820,158,7284,081,266,6544,814,557,8225,825,294,4988,782,479,67610,116,793,93712,532,841,02810,318,312,851
Net income
1.35b
-42.76%
122,117,123297,182,764315,559,119454,071,087185,806,390244,291,460354,495,205430,491,010542,023,195540,705,102599,221,880606,501,0701,218,737,6791,343,856,0072,362,756,4841,352,379,242
CFO
155m
-95.54%
210,177,689318,211,329299,717,830070,128,56955,322,427105,904,047131,877,728631,641,569114,652,88772,366,62968,925,4491,586,172,733528,693,7143,487,736,416155,457,433
Dividend
Jul 19, 20240.3 CNY/sh
Earnings
May 22, 2025

Profile

Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of medicine primarily in China. The company operates through Chemical and Biological Medicine, and Health Industry segments. It offers drugs for cardiac and premature ventricular beats, sinus bradycardia, chronic heart failure, integrated rhythm regulation, cold and respiratory, cardiovascular and cerebrovascular diseases, diabetes field, tumor medication, and others. The company sells its products through physical display and online. Shijiazhuang Yiling Pharmaceutical Co., Ltd. was founded in 1992 and is based in Shijiazhuang, China.
URL
https://www.yiling.cn/
IPO date
Jul 28, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
10,318,313
-17.67%
12,532,841
23.88%
Cost of revenue
7,137,294
8,989,534
Unusual Expense (Income)
NOPBT
3,181,019
3,543,307
NOPBT Margin
30.83%
28.27%
Operating Taxes
339,909
423,821
Tax Rate
10.69%
11.96%
NOPAT
2,841,110
3,119,485
Net income
1,352,379
-42.76%
2,362,756
75.82%
Dividends
(835,353)
Dividend yield
2.17%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
605,847
656,326
Long-term debt
625,129
230,097
Deferred revenue
335,023
Other long-term liabilities
352,374
1
Net debt
(1,566,262)
(2,366,757)
Cash flow
Cash from operating activities
155,457
3,487,736
CAPEX
(310,834)
Cash from investing activities
(899,218)
Cash from financing activities
(220,595)
FCF
577,252
4,110,506
Balance
Cash
1,146,481
2,422,660
Long term investments
1,650,757
830,520
Excess cash
2,281,322
2,626,537
Stockholders' equity
8,165,065
8,648,903
Invested Capital
10,727,009
9,036,205
ROIC
28.75%
33.14%
ROCE
24.21%
30.37%
EV
Common stock shares outstanding
1,670,635
1,670,705
Price
23.07
-23.00%
29.96
52.86%
Market cap
38,541,555
-23.00%
50,054,333
52.86%
EV
36,963,567
47,687,577
EBITDA
3,728,427
3,994,776
EV/EBITDA
9.91
11.94
Interest
38,901
33,796
Interest/NOPBT
1.22%
0.95%